C81.34
Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb
Clinical Classification Guidelines
Medical Intelligence & Overview
Lymphocyte-depleted Hodgkin lymphoma is a rare form of Hodgkin lymphoma, a type of cancer originating from lymphatic tissue. This specific subtype, coded as C81.34 in the ICD-10 classification, primarily affects lymph nodes located in the axilla (armpit area) and the upper limb. It is characterized by a reduction in lymphocytes, which are essential white blood cells involved in the immune response. The disease tends to be more aggressive compared to other Hodgkin lymphoma subtypes, often requiring prompt diagnosis and treatment. Awareness of its signs can help in early detection and management.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal lymphocyte development History of immune system suppression or immunodeficiency Previous exposure to certain environmental factors or infections Family history of lymphatic or hematological cancers
Key Symptoms: Swollen or enlarged lymph nodes in the axilla or upper limb Persistent fatigue or weakness Unexplained weight loss Fever or night sweats Itching skin Pain or discomfort at the sites of enlarged lymph nodes Additional symptoms could include cough or chest discomfort if the disease spreads In some cases, symptoms might be subtle or absent in early stages
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a combination of clinical evaluation, imaging tests, and tissue biopsy. Initially, physical exams may reveal enlarged lymph nodes in affected regions. Imaging techniques such as computed tomography (CT) scans or positron emission tomography (PET) scans help locate and assess the extent of lymph node involvement. The definitive diagnosis is obtained through a biopsy of affected lymph nodes, examining tissue under the microscope for characteristic features of lymphocyte-depleted Hodgkin lymphoma. Additional laboratory tests may include blood tests and immunohistochemistry to aid in diagnosis and staging. Accurate identification of the subtype is crucial because it influences treatment strategies.
Treatment Protocols: Treatment options for lymphocyte-depleted Hodgkin lymphoma often involve systemic therapies. Common approaches include chemotherapy regimens tailored to high-grade lymphomas, such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) or other combination therapies. In certain cases, radiation therapy may be used to target specific lymph node regions. Advanced or aggressive disease might require stem cell transplantation or targeted therapies. Due to the disease's aggressive nature, close follow-up and supportive care are essential to address side effects and monitor for recurrence. Multidisciplinary care involving hematologists, oncologists, and supportive specialists plays a vital role in optimizing outcomes.
Clinical Advice & FAQs
Billing Guidance
Is C81.34 a billable ICD-10 code?
Yes, C81.34 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.34?
Clinical documentation must specify the nature of Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb and any associated comorbidities for accurate reporting.
Cite this Clinical Reference